The RESILIENCE clinical trial has been designed to explore the effectiveness and safety of remote ischemic conditioning (RIC) ...

这些被质疑的论文所涉及的学术不端，主要是一图多用，图片PS等。目前仅有少数几篇被质疑论文得到作者回应，作者回应称“论文中无意的错误并不影响实验结论”。 截至2024年9月5日，Gregg L.

Southwest Research Institute (SwRI) is collaborating with The University of Texas at San Antonio (UTSA) to explore and ...

Naomi Dempsey, MD, discussed developments in the HER2-positive breast cancer space, including personalized approaches, less ...

Southwest Research Institute (SwRI) is collaborating with The University of Texas at San Antonio (UTSA) to explore and ...

SwRI and UTSA will work together to combat the growing threat antimicrobial resistance poses to global health by developing a proof-of-concept platform to potentially create a whole library of new ...

The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company), a Phase 3 clinical-stage pharmaceutical company with a ...

In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.

ASX health stocks have fallen this week but Morgans analyst Scott Power is more optimistic after the Fed cut the cash rate by ...

About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers ...

Adaptimmune received FDA approval for Tecelra, with a 39% response rate in synovial sarcoma. See why I rate ADAP stock as a ...